Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Leukemia

• Publication date

  1994-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 8152260
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The generation of human natural killer cells from CD34+/DR- primitive progenitors in long-term bone marrow culture.

  1992cited by this paper
• CD16- CD56+ natural killer cells after bone marrow transplantation.

  1992cited by this paper
• Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF

  1992cited by this paper
• A gamma delta+ T-cell leukemia bearing a novel t(8;14)(q24;q11) translocation demonstrates spontaneous in vitro natural killer-like activity.

  1992cited by this paper
• Interleukin-2-activated natural killer cells can support hematopoiesis in vitro and promote marrow engraftment in vivo.

  1992cited by this paper
• Biology and clinical relevance of human natural killer cells.

  1990cited by this paper
• Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood

  1990cited by this paper
• Natural killer lines and clones with apparent antigen specificity

  1990cited by this paper
• Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. I. Stimulatory role of a variety of mesenchymal cell activators and inhibitory role of TGF-beta.

  1990cited by this paper
• Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis.

  1990cited by this paper
• Comparative study of automated versus manual extraction of DNA from clinical specimens.

  1990cited by this paper
• Diversity and organization of human T cell receptor delta variable gene segments

  1989cited by this paper
• Double-negative (CD4-CD8-) lymphocytes bearing T-cell receptor alpha and beta chains in normal human skin.

  1989cited by this paper
• Characterization of the interleukin 2 receptor beta chain using three distinct monoclonal antibodies.

  1989cited by this paper
• Detection of Epstein-Barr virus DNA by polymerase chain reaction in blood and tissue biopsies from patients with Sjogren's syndrome

  1989cited by this paper
• Functional heterogeneity of Leu 19"bright"+ and Leu 19"dim"+ lymphokine-activated killer cells.

  1989cited by this paper
• Establishment and characterization of a unique human cell line that proliferates dependently on GM‐CSF, IL‐3, or erythropoietin

  1989cited by this paper
• CD11a-c/CD18 and GP84 (LB-2) adhesion molecules on human large granular lymphocytes and their participation in natural killing.

  1988cited by this paper
• NK susceptibility varies inversely with target cell class I HLA antigen expression.

  1987cited by this paper
• Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines.

  1987cited by this paper
• Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis

  1986cited by this paper
• Aggressive natural killer cell leukemia in an adult with establishment of an NK cell line.

  1986cited by this paper
• Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

  1985cited by this paper
• TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells).

  1985cited by this paper
• Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.

  1984cited by this paper
• Phenotypic and functional heterogeneity of human cloned natural killer cell lines

  1983cited by this paper
• Childhood lymphoblastic leukemia with natural killer activity: establishment of the leukemia cell lines retaining the activity.

  1982cited by this paper

• Current development and challenges of NK cell-based immunotherapy for gastrointestinal cancers.

  2026cites this paper
• Cultivation strategy optimisation for NK-92 cell line expansion in static conditions.

  2026cites this paper
• Impact of Image Representation on Deep Learning-Based Single-Cell Classification by Holographic Imaging Flow Cytometry

  2026cites this paper
• Non-Genetically Modified Adoptive Cell Therapies for Solid Tumors: Current Landscape and Future Challenges

  2026cites this paper
• Flavones and Aminoflavones Increase the Cytotoxicity of NK Cells in Human Non‐Small Cell Lung Cancer

  2026cites this paper
• Development and evaluation of an inhalable nanoemulsion system for enhancing NK cell function against osteosarcoma pulmonary metastases.

  2026cites this paper
• The clinical landscape of CAR NK cells

  2025cites this paper
• CAR-NK cell therapy: promise and challenges in solid tumors

  2025cites this paper
• Single-chain variable fragment affinity tuning can optimize anti-AML CAR-NK cell functionality

  2025cites this paper
• Application and prospects of genetic engineering in CAR-NK cell therapy

  2025cites this paper
• JEG-3 Trophoblast Cells Influence ILC-like Transformation of NK Cells In Vitro

  2025cites this paper
• CAR-NK cell therapy combined with checkpoint inhibition induces an NKT cell response in glioblastoma

  2025cites this paper
• Characterization of lysate from NK-92 cells and its potential use as an immunotherapeutic modality.

  2025cites this paper
• FLU-v, a Broad-Spectrum Peptide-Based Influenza Vaccine, Induces NK Cell Activating IgG1 and IgG3 Subclass Antibodies in Humans

  2025cites this paper
• Enhancement of NK cell activity via DNA-sensing inhibition by Poxin transgene.

  2025cites this paper
• Expanding Immunotherapy Beyond CAR T Cells: Engineering Diverse Immune Cells to Target Solid Tumors

  2025cites this paper
• Engineered natural killer cells for cancer therapy.

  2025cites this paper
• The Role of MICA/B Molecules and the NKG2D Receptor in the Interaction Between NK-92 Cells and JEG-3 Cells

  2025cites this paper
• Leveraging the heterogeneity of the NK cell repertoire for the development of immunotherapies for acute leukemia

  2025cites this paper
• Does a natural killer need a CAR?

  2025cites this paper
• Senescence, NK cells, and cancer: navigating the crossroads of aging and disease

  2025cites this paper
• Chimeric antigen receptor natural killer (CAR-NK) cells: from preclinical promise to clinical reality in cancer immunotherapy

  2025cites this paper
• Colorectal Organoids: Models, Imaging, Omics, Therapy, Immunology, and Ethics

  2025cites this paper
• CAR-NK cell for gynecological cancers: immune microenvironment remodeling and immunotherapeutic strategies

  2025cites this paper
• NK cell‐based immunotherapy for hepatocellular carcinoma: Challenges and opportunities

  2025cites this paper
• Targeting HER2-Positive Solid Tumors with CAR NK Cells: CD44 Expression Is a Critical Modulator of HER2-Specific CAR NK Cell Efficacy

  2025cites this paper
• Natural born Killers: Harnessing NK cells to treat cancer.

  2025cites this paper
• Therapeutic effects of NK cell-derived EVs on cancer: Current advances and future treatment strategies

  2025cites this paper
• Chimeric Cytokine Receptor TGF-β RⅡ/IL-21R Improves CAR-NK Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Gastric Cancer.

  2025cites this paper
• Trying to Kill a Killer; Impressive Killing of Patient Derived Glioblastoma Cultures Using NK-92 Natural Killer Cells Reveals Both Sensitive and Highly Resistant Glioblastoma Cells

  2025cites this paper
• Targeting mutated KRAS by HLA-A*02:01 restricted anti-KRAS TCR-mimic CAR and bispecific T cell engager

  2025cites this paper
• Lipoprotein Association Fluorometry (LAF) as a Semi‐Quantitative Characterization Tool to Assess Extracellular Vesicle‐Lipoprotein Binding

  2025cites this paper
• Chimeric antigen receptor NK-92 cell function is modulated by HLA class I expression of target cells

  2025cites this paper
• MYC controls STING levels to downregulate inflammatory signaling in breast cancer cells upon DNA damage

  2025cites this paper
• The Application of iPSCs in Tumour Immunotherapy

  2025cites this paper
• Prospects and limitations of NK cell adoptive therapy in clinical applications

  2025cites this paper
• UTY coordinates with UTX to repress NK cell development and maturation in males.

  2025cites this paper
• CAR NK cell therapy for solid tumors: potential and challenges.

  2025cites this paper
• A common polymorphism in the human immunoreceptor NKp65 determines ligand interaction, cell surface expression and function

  2025cites this paper
• NK92 cells stably transfected with CD16 are efficient against multiple myeloma cells ex vivo and in vivo, especially if combined with daratumumab

  2025cites this paper
• Epigenetic modulation elicits an NK cell-mediated immune response in urothelial carcinoma

  2025cites this paper
• The Natural Killer Cell Line NK-92 and Its Genetic Variants: Impact on NK Cell Research and Cancer Immunotherapy

  2025cites this paper
• Molecular basis of β2 integrin activation by talin unveils subunit-specific mechanisms of integrin signaling

  2025cites this paper
• ErbB2/HER2-targeted CAR-NK cells eliminate breast cancer cells in an organoid model that recapitulates tumor progression.

  2025cites this paper
• Natural killer cell–based immunotherapy for cancer

  2025cites this paper
• CAR-NK cell therapy in multiple myeloma: from preclinical and clinical landscape to joining the force for treatment strategies optimization

  2025cites this paper
• Acidic pH can attenuate immune killing through inactivation of perforin

  2025cites this paper
• Establishment and Multidimensional Characterization of a Novel EBV-negative Human Type Ⅰ Natural Killer T Cell Line NKT617.

  2025cites this paper
• Optimizing Natural Killer Cellular Therapy in Acute Myeloid Leukemia.

  2025cites this paper
• Shaping the glioblastoma microenvironment to enhance CAR-NK immunotherapy

  2025cites this paper
• Targeting SHP‐1‐Mediated Inhibition of STAT3 and ERK Signalling Pathways Rescues the Hyporesponsiveness of MHC‐I‐Deficient NK‐92MI

  2025cites this paper
• NK92 cells and peripheral blood NK cells respond oppositely upon dasatinib treatment

  2024cites this paper
• Dual Targeting of Glioblastoma Cells with Bispecific Killer Cell Engagers Directed to EGFR and ErbB2 (HER2) Facilitates Effective Elimination by NKG2D-CAR-Engineered NK Cells

  2024cites this paper
• Development of NK cell-based cancer immunotherapies through receptor engineering

  2024cites this paper
• NK cells as powerful therapeutic tool in cancer immunotherapy

  2024cites this paper
• Immunoregulatory functions and therapeutic potential of natural killer cell-derived extracellular vesicles in chronic diseases

  2024cites this paper
• Manufacturing CAR-NK against tumors: Who is the ideal supplier?

  2024cites this paper
• Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside

  2024cites this paper
• Natural Killer Cell Lysate Fractions Affect Trophoblast Cell Proliferation In Vitro

  2024cites this paper
• Reprogramming natural killer cells for cancer therapy.

  2024cites this paper
• Current Treatment Options for Renal Cell Carcinoma: Focus on Cell-Based Immunotherapy

  2024cites this paper
• C/EBPβ-dependent autophagy inhibition hinders NK cell function in cancer

  2024cites this paper
• Lipid nanoparticle‐mediated RNA delivery for immune cell modulation

  2024cites this paper
• Natural killer cells: a new promising source for developing chimeric antigen receptor anti-cancer cells in hematological malignancies

  2024cites this paper
• Nature killer cell for solid tumors: Current obstacles and prospective remedies in NK cell therapy and beyond.

  2024cites this paper
• Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization

  2024cites this paper
• Antibody-targeted T cells and natural killer cells for cancer immunotherapy

  2024cites this paper
• Lightweight CNN efficiently discriminates ovarian cancer cells from a tumor microenvironment via holographic imaging flow cytometry

  2024cites this paper
• Empowering Natural Killer Cells to Combat Acute Myeloid Leukemia: Perspective on CAR-NK Cell Therapy

  2024cites this paper
• Bispecific killer cell engagers employing species cross-reactive NKG2D binders redirect human and murine lymphocytes to ErbB2/HER2-positive malignancies

  2024cites this paper
• Revolutionizing the treatment for nasopharyngeal cancer: the impact, challenges and strategies of stem cell and genetically engineered cell therapies

  2024influential citation
• Apoptotic Receptors and CD107a Expression by NK Cells in an Interaction Model with Trophoblast Cells

  2024cites this paper
• A phosphoramidate modification of FUDR, NUC-3373, causes DNA damage and DAMPs release from colorectal cancer cells, potentiating lymphocyte-induced cell death

  2024cites this paper
• Harnessing natural killer cells engineering for cancer immunotherapy

  2024cites this paper
• Anti-Mesothelin CAR-NK cells as a novel targeted therapy against cervical cancer

  2024cites this paper
• STAT3 in acute myeloid leukemia facilitates natural killer cell-mediated surveillance

  2024cites this paper
• Endoglin Regulates Intercellular Interactions between Trophoblast and Natural Killer Cells

  2024cites this paper
• HLA-E-VL9 antibodies enhance NK cell and CD8+ T cell cytotoxicity against HIV-infected CD4+ T cells

  2024cites this paper
• Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification

  2024cites this paper
• Natural killer cell‐related anti‐tumour adoptive cell immunotherapy

  2024cites this paper
• Contemporary Approaches to Immunotherapy of Solid Tumors

  2024cites this paper
• NK Cytotoxicity Mediated by NK-92 Cell Lines Expressing Combinations of Two Allelic Variants for FCGR3

  2024cites this paper
• Analysis of Cytotoxic Granules and Constitutively Produced Extracellular Vesicles from Large Granular Lymphocytic Leukemia Cell Lines

  2024cites this paper
• Micropreparative Cell Lysate Fractionation in Studying the Effect of Natural Killer Cells on Phenotype, Migration and Apoptosis of Trophoblast Cells in vitro

  2024cites this paper
• Large Extracellular Vesicles Derived from Natural Killer Cells Affect the Functions of Monocytes

  2024influential citation
• Non-viral approaches in CAR-NK cell engineering: connecting natural killer cell biology and gene delivery

  2024cites this paper
• Molecular Basis of β2 Integrin Activation by Talin Unveils Species-Specific Mechanisms of Integrin Signaling

  2024cites this paper
• Antitumor activity of genetically engineered NK-cells in non-hematological solid tumor: a comprehensive review

  2024cites this paper
• Three-Dimensional Model Analysis Revealed Differential Cytotoxic Effects of the NK-92 Cell Line and Primary NK Cells on Breast and Ovarian Carcinoma Cell Lines Mediated by Variations in Receptor–Ligand Interactions and Soluble Factor Profiles

  2024cites this paper
• CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside

  2024cites this paper
• BET inhibitors drive Natural Killer activation in non-small cell lung cancer via BRD4 and SMAD3

  2024cites this paper
• High-throughput proliferation and activation of NK-92MI cell spheroids via a homemade one-step closed bioreactor in pseudostatic cultures for immunocellular therapy

  2024cites this paper
• Optimisation of a primary human CAR‐NK cell manufacturing pipeline

  2024cites this paper
• Targeting the aminopeptidase ERAP enhances antitumor immunity by disrupting the NKG2A-HLA-E inhibitory checkpoint.

  2024cites this paper
• Granulocyte Colony Stimulating Factor-Mobilized Peripheral Blood Mononuclear Cells: An Alternative Cellular Source for Chimeric Antigen Receptor Therapy

  2024cites this paper
• Imaging CAR-NK cells targeted to HER2 ovarian cancer with human sodium-iodide symporter-based positron emission tomography

  2024cites this paper
• CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors

  2024cites this paper
• Expansion Of Natural Killer Cells and Efficacy Against Hematologic Malignancies

  2023cites this paper
• Harnessing the Power of CAR-NK Cells: A Promising Off-the-Shelf Therapeutic Strategy for CD38-Positive Malignancies.

  2023cites this paper
• Integration of ζ-deficient CARs into the CD3-zeta gene conveys potent cytotoxicity in T and NK cells

  2023cites this paper